Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision Care for Major Depressive Disorder
NCT06580041Phase 4Enrolling by invitation
- Sponsor
- University of California, San Francisco
- Start
- Nov 2024
- Primary completion
- Sep 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of pramipexole, methylphenidate, phenelzine in major depressive disorder (MDD), sponsored by University of California, San Francisco. Started Nov 2024; status: enrolling by invitation.
02
Drugs
pramipexolemethylphenidatephenelzine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06580041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06580041.